The aim of pharmaceutical development is to design a qualityproduct and its manufacturing process to consistently deliver theintended performance of the product. Many new regulatory initiativeswere introduced in the last decade e.g. Pharmaceutical GoodManufacturing Process (GMP) for 21st Century,1 Quality by Design(QbD).2 Process Analytical Technology (PAT)3 and Quality Systeminitiative.4 All these approaches provide a better understanding of theproducts. Since pharmaceutical development takes approximately 10years with a cost of close to a billion dollars, a tool is required thatprovides a structured plan. Such a tool is known as Target ProductProfile (TPP).5–7 It is simply a planning tool in the development stageof Pharmaceutical R&D process, in which a drug candidate fromdiscovery is subjected to clinical development to determine safety,efficacy, and marketing suitability. This concept was originated in1997 through discussions between FDA and a Clinical Developmentworking group for improving sponsor and FDA interactions.5,6 Theworking committee recommended the use of a “template” thatsummarizes a drug labeling concept to help focus discussions and aidin the understanding between sponsors and the FDA.7 The outcome ofthe discussions resulted in minimization of the risk of late stage drugdevelopment process, increasing the probability of obtaining optionalsafety and efficacy data in a timely manner, improving labeling contentand possible minimization of time involved in drug development.7
The aim of pharmaceutical development is to design a quality<br>product and its manufacturing process to consistently deliver the<br>intended performance of the product. Many new regulatory initiatives<br>were introduced in the last decade e.g. Pharmaceutical Good<br>Manufacturing Process (GMP) for 21st Century,1<br> Quality by Design<br>(QbD).2<br> Process Analytical Technology (PAT)3<br> and Quality System<br>initiative.4<br> All these approaches provide a better understanding of the<br>products. Since pharmaceutical development takes approximately 10<br>years with a cost of close to a billion dollars, a tool is required that<br>provides a structured plan. Such a tool is known as Target Product<br>Profile (TPP).5–7 It is simply a planning tool in the development stage<br>of Pharmaceutical R&D process, in which a drug candidate from<br>discovery is subjected to clinical development to determine safety,<br>efficacy, and marketing suitability. This concept was originated in<br>1997 through discussions between FDA and a Clinical Development<br>working group for improving sponsor and FDA interactions.5,6 The<br>working committee recommended the use of a “template” that<br>summarizes a drug labeling concept to help focus discussions and aid<br>in the understanding between sponsors and the FDA.7<br> The outcome of<br>the discussions resulted in minimization of the risk of late stage drug<br>development process, increasing the probability of obtaining optional<br>safety and efficacy data in a timely manner, improving labeling content<br>and possible minimization of time involved in drug development.7
正在翻译中..